Literature DB >> 26465839

"Farmácia Popular do Brasil" Program: characterization and evolution between 2004 and 2012.

Rondineli Mendes da Silva1, Rosangela Caetano2.   

Abstract

The "Farmácia Popular do Brasil" Program (PFPB) aims to improve access to medicines, offering subsidized products. It is structured in an arrangement involving public and private sectors. The paper described the organization and expansion of the PFPB and examined the reference price (RP) of the medicines paid by the government, between 2004 and 2012. It is an exploratory study of quantitative and qualitative approach, developed from the literature review and analysis of public documents. Quantitative data were collected from the Ministry of Health and Electronic System of Citizens Information Services. The PFPB is organized in two delivery models: public owned facilities (Rede Própria) and accredited private retail pharmacies (Aqui Tem Farmácia Popular-ATFP). The ATFP has allowed its own expansion, from 2006. Antihypertensives, antidiabetics and antiasthmatics were exempt from copayment, since 2011. The expansion of the ATFP Program was significant, for facilities and covered municipalities, 750% and 528%, respectively. The RP was reduced by 33.6% on average (ranging from 23-52%) for medicines available since the beginning of the ATFP. The expansion was performed with the actions hitherto unprecedented, as copayment and accreditation of private retail pharmacies.

Mesh:

Substances:

Year:  2015        PMID: 26465839     DOI: 10.1590/1413-812320152010.17352014

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  13 in total

Review 1.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

2.  Use of and access to oral and injectable contraceptives in Brazil.

Authors:  Mareni Rocha Farias; Silvana Nair Leite; Noemia Urruth Leão Tavares; Maria Auxiliadora Oliveira; Paulo Sergio Dourado Arrais; Andréa Dâmaso Bertoldi; Tatiane da Silva Dal Pizzol; Vera Lucia Luiza; Luiz Roberto Ramos; Sotero Serrate Mengue
Journal:  Rev Saude Publica       Date:  2016-12       Impact factor: 2.106

3.  Costs of Public Pharmaceutical Services in Rio de Janeiro Compared to Farmácia Popular Program.

Authors:  Rondineli Mendes da Silva; Rosângela Caetano
Journal:  Rev Saude Publica       Date:  2016-12-22       Impact factor: 2.106

4.  Access to medicines for chronic diseases in Brazil: a multidimensional approach.

Authors:  Maria Auxiliadora Oliveira; Vera Lucia Luiza; Noemia Urruth Leão Tavares; Sotero Serrate Mengue; Paulo Sergio Dourado Arrais; Mareni Rocha Farias; Tatiane da Silva Dal Pizzol; Luiz Roberto Ramos; Andréa Dâmaso Bertoldi
Journal:  Rev Saude Publica       Date:  2016-12       Impact factor: 2.106

5.  Corporate social responsibility to improve access to medicines: the case of Brazil.

Authors:  Halla Thorsteinsdóttir; Natasha Ovtcharenko; Jillian Clare Kohler
Journal:  Global Health       Date:  2017-02-21       Impact factor: 4.185

Review 6.  Applying a health system perspective to the evolving Farmácia Popular medicines access programme in Brazil.

Authors:  Vera L Luiza; Luisa A Chaves; Monica R Campos; Andrea D Bertoldi; Rondineli M Silva; Maryam Bigdeli; Dennis Ross-Degnan; Isabel C M Emmerick
Journal:  BMJ Glob Health       Date:  2018-02-07

7.  BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management.

Authors:  Victor G Rodwin; Guilhem Fabre; Rafael F Ayoub
Journal:  Int J Health Policy Manag       Date:  2018-03-01

8.  Factors associated with hospital admissions due to hypertension.

Authors:  Rosimery Cruz de Oliveira Dantas; João Paulo Teixeira da Silva; Davidson Cruz de Oliveira Dantas; Ângelo Giuseppe Roncalli
Journal:  Einstein (Sao Paulo)       Date:  2018-09-21

9.  [Costs attributable to obesity, hypertension, and diabetes in the Unified Health System, Brazil, 2018Costos atribuibles a la obesidad, la hipertensión y la diabetes en el Sistema Único de Salud de Brasil, 2018].

Authors:  Eduardo Augusto Fernandes Nilson; Rafaella da Costa Santin Andrade; Daniela Aquino de Brito; Michele Lessa de Oliveira
Journal:  Rev Panam Salud Publica       Date:  2020-04-10

Review 10.  Use of health outcome and health service utilization indicators as an outcome of access to medicines in Brazil: perspectives from a literature review.

Authors:  Luisa Arueira Chaves; Danielle Maria de Souza Serio Dos Santos; Monica Rodrigues Campos; Vera Lucia Luiza
Journal:  Public Health Rev       Date:  2019-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.